112 related articles for article (PubMed ID: 26416293)
1. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment.
Chu CH; Chou CY; Lin FL
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e81-e83. PubMed ID: 26416293
[No Abstract] [Full Text] [Related]
2. Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed.
Frouin E; Sebille G; Freudenberger S; Menecier B; Quoix E; Cribier B; Lipsker D
Br J Dermatol; 2012 Jun; 166(6):1359-60. PubMed ID: 22182200
[No Abstract] [Full Text] [Related]
3. Lipodermatosclerosis secondary to pemetrexed use.
Shuster M; Morley K; Logan J; Sequist LV; Shaw A; Fidias P; Kroshinsky D
J Thorac Oncol; 2015 Mar; 10(3):e11-2. PubMed ID: 25695225
[No Abstract] [Full Text] [Related]
4. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
7. Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer.
Jung YD; Lee SB; Jung YW; Song JS; Woo IS
Korean J Intern Med; 2017 Sep; 32(5):923-925. PubMed ID: 28298078
[No Abstract] [Full Text] [Related]
8. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.
Ikesue H; Watanabe H; Hirano M; Chikamori A; Suetsugu K; Ryokai Y; Egashira N; Yamada T; Ikeda M; Iwama E; Harada T; Takayama K; Nakanishi Y; Masuda S
Biol Pharm Bull; 2015; 38(8):1192-8. PubMed ID: 26235582
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed and interstitial lung disease.
Adhikari B; Dongol RM; Baral D; Hewett Y; Shah BK
Acta Oncol; 2016; 55(4):521-2. PubMed ID: 26366501
[No Abstract] [Full Text] [Related]
11. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed-Induced Syncope.
Chapman D; Taj A
Am J Ther; 2019; 26(4):e548-e549. PubMed ID: 29927772
[No Abstract] [Full Text] [Related]
13. Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.
Ishikawa K; Sakai T; Saito-Shono T; Miyawaki M; Osoegawa A; Sugio K; Ono A; Mori H; Nishida H; Yokoyama S; Okamoto O; Fujiwara S; Hatano Y
J Dermatol; 2016 Sep; 43(9):1071-4. PubMed ID: 26992088
[TBL] [Abstract][Full Text] [Related]
14. Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed.
Park K
J Control Release; 2018 Aug; 284():250-251. PubMed ID: 30097256
[No Abstract] [Full Text] [Related]
15. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.
Assayag M; Rouvier P; Gauthier M; Costel G; Cluzel P; Mercadal L; Deray G; Isnard Bagnis C
BMC Cancer; 2017 Nov; 17(1):770. PubMed ID: 29145816
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
17. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
18. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
Elsoueidi R; Lander MJ; Richa EM; Adane ED
J Oncol Pharm Pract; 2016 Apr; 22(2):271-4. PubMed ID: 25908647
[TBL] [Abstract][Full Text] [Related]
19. Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.
Pérez-Moreno MA; Cotrina-Luque J; Galván-Banqueri M; Flores-Moreno S; Bautista-Paloma FJ; Calleja-Hernández MÁ
J Chemother; 2015; 27(6):371-7. PubMed ID: 25971603
[TBL] [Abstract][Full Text] [Related]
20. Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer.
Declercq I; Lievens Y; Verbeken E; Vansteenkiste J
J Thorac Oncol; 2008 Jun; 3(6):662-3. PubMed ID: 18520810
[No Abstract] [Full Text] [Related]
[Next] [New Search]
